Risk factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli in a county of southern Sweden

Infection and Drug Resistance

Volumn 6, Issue , 2013, Pages 93-97

  Tham, Johan ^a   Odenholt, Inga ^a   Walder, Mats ^a   Andersson, Lina ^a   Melander, Eva ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b Laboratory Medicine   (Sweden)

Author keywords

Enterobacteriaceae; Escherichia coli; Extended spectrum lactamase; Resistant bacteria; Risk factors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFADROXIL; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BLOOD CULTURE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; EGYPT; ENDEMIC DISEASE; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; NONHUMAN; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; SURGICAL WARD; SWEDEN; TRAVEL; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; URINE CULTURE;

EID: 84884668698     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S46290     Document Type: Article

References (26)

1. Ben-Ami R, Rodriguez-Bano J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682-690.
2. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913-920.
3. Alsterlund R, Carlsson B, Gezelius L, Haeggman S, Olsson-Liljequist B. Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand J Infect Dis. 2009;41(6-7): 410-415.
4. Lytsy B, Sandegren L, Tano E, Torell E, Andersson DI, Melhus A. The first major extended-spectrum beta-lactamase outbreak in Scandinavia was caused by clonal spread of a multiresistant Klebsiella pneumoniae producing CTX-M-15. APMIS. 2008;116(4):302-308.
5. Stromdahl H, Tham J, Melander E, Walder M, Edquist PJ, Odenholt I. Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden. Eur J Clin Microbiol Infect Dis. 2011;30(10):1159-1162.
6. European Antimicrobial Resistance Surveillance Network. Available from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/database.aspx.
7. Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin Microbiol Rev. 2004;17(4):863-893.
8. Ransjo U, Lytsy B, Melhus A, et al. Hospital outbreak control requires joint efforts from hospital management, microbiology and infection control. J Hosp Infect. 2010;76(1):26-31.
9. Kaier K, Hagist C, Frank U, Conrad A, Meyer E. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant Staphylococcus aureus infection and Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30(4):346-353.
10. Andersson H, Lindholm C, Iversen A, et al. Prevalence of antibiotic-resistant bacteria in residents of nursing homes in a Swedish municipality: healthcare staff knowledge of and adherence to principles of basic infection prevention. Scand J Infect Dis. 2012;44(9):641-649.
11. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23(3): 163-167.
12. Tham J, Odenholt I, Walder M, Brolund A, Ahl J, Melander E. Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis. 2010;42(4):275-280.
13. Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother. 2010;54(9):3564-3568.
14. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159-166.
15. Ruppe E, Pitsch A, Tubach F, et al. Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards. Eur J Clin Microbiol Infect Dis. 2012;31(3):319-325.
16. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae - EUCAST and CLSI breakpoints. Clin Microbiol Infect. 2008;14 Suppl 1:169-174.
17. Wollin HHMTR, editor. Infektionsdiagnostik 1:2: Infektioner i mag- och tarmkanalen, 2nd ed [Infection Diagnostics 1:2: Infections of the gastrointestinal tract]. Solna, Sweden: Smittskyddsinstitutet; 2002.
18. Referensmetodik för laboratoriediagnostik vid kliniskt mikrobiologiska laboratorier. [Reference Methodology for laboratory diagnostics in clinical microbiology laboratories]. Available from: http://whttp://www.referensmetodik.smi.se/w/Referensmetodik:_Tarminfektioner. Accessed July 12, 2012.
19. El Kholy A, Baseem H, Hall GS, Procop GW, Longworth DL. Antimicrobial resistance in Cairo, Egypt 1999-2000: a survey of five hospitals. J Antimicrob Chemother. 2003;51(3):625-630.
20. Hammami S, Saidani M, Ferjeni S, Aissa I, Slim A, Boutiba-Ben Boubaker I. Characterization of extended spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections in Tunisia. Microb Drug Resist. 2013;19(3):231-236.
21. Sankar S, Narayanan H, Kuppanan S, Nandagopal B. Frequency of extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacilli in a 200-bed multi-specialty hospital in Vellore district, Tamil Nadu, India. Infection. 2012;40(4):425-429.
22. Luvsansharav UO, Hirai I, Nakata A, et al. Prevalence of and risk factors associated with faecal carriage of CTX-M beta-lactamase-producing Enterobacteriaceae in rural Thai communities. J Antimicrob Chemother. 2012;67(7):1769-1774.
23. Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect. 2008;57(6): 441-448.
24. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32(8):1162-1171.
25. Harris AD, Perencevich EN, Johnson JK, et al. Patient-to-patient transmission is important in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae acquisition. Clin Infect Dis. 2007;45(10): 1347-1350.
26. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007;55(3): 254-259.